CYTK
Price
$51.48
Change
-$0.34 (-0.66%)
Updated
Nov 4 closing price
One day until earnings call
ERNA
Price
$1.07
Change
-$0.02 (-1.83%)
Updated
Nov 4 closing price
Ad is loading...

CYTK vs ERNA

Header iconCYTK vs ERNA Comparison
Open Charts CYTK vs ERNABanner chart's image
Cytokinetics
Price$51.48
Change-$0.34 (-0.66%)
Volume$718.73K
CapitalizationN/A
Eterna Therapeutics
Price$1.07
Change-$0.02 (-1.83%)
Volume$10.27K
CapitalizationN/A
View a ticker or compare two or three
CYTK vs ERNA Comparison Chart
Loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ERNA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
CYTK vs. ERNA commentary
Nov 05, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a StrongSell and ERNA is a Buy.

COMPARISON
Comparison
Nov 05, 2024
Stock price -- (CYTK: $51.48 vs. ERNA: $1.07)
Brand notoriety: CYTK and ERNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 64% vs. ERNA: 24%
Market capitalization -- CYTK: $6.06B vs. ERNA: $5.79M
CYTK [@Biotechnology] is valued at $6.06B. ERNA’s [@Biotechnology] market capitalization is $5.79M. The market cap for tickers in the [@Biotechnology] industry ranges from $498.83B to $0. The average market capitalization across the [@Biotechnology] industry is $2.8B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green whileERNA’s FA Score has 0 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • ERNA’s FA Score: 0 green, 5 red.
According to our system of comparison, CYTK is a better buy in the long-term than ERNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 2 TA indicator(s) are bullish while ERNA’s TA Score has 6 bullish TA indicator(s).

  • CYTK’s TA Score: 2 bullish, 6 bearish.
  • ERNA’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, ERNA is a better buy in the short-term than CYTK.

Price Growth

CYTK (@Biotechnology) experienced а -1.49% price change this week, while ERNA (@Biotechnology) price change was +4.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.74%. For the same industry, the average monthly price growth was +10.27%, and the average quarterly price growth was +7.68%.

Reported Earning Dates

CYTK is expected to report earnings on Feb 20, 2025.

ERNA is expected to report earnings on May 11, 2023.

Industries' Descriptions

@Biotechnology (-1.74% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($6.06B) has a higher market cap than ERNA($5.79M). CYTK YTD gains are higher at: -38.340 vs. ERNA (-40.390). ERNA has higher annual earnings (EBITDA): -20.12M vs. CYTK (-459.67M). CYTK has more cash in the bank: 1.06B vs. ERNA (2.59M). ERNA has less debt than CYTK: ERNA (49.2M) vs CYTK (790M). CYTK has higher revenues than ERNA: CYTK (3.13M) vs ERNA (162K).
CYTKERNACYTK / ERNA
Capitalization6.06B5.79M104,629%
EBITDA-459.67M-20.12M2,285%
Gain YTD-38.340-40.39095%
P/E RatioN/AN/A-
Revenue3.13M162K1,935%
Total Cash1.06B2.59M40,874%
Total Debt790M49.2M1,606%
FUNDAMENTALS RATINGS
CYTK vs ERNA: Fundamental Ratings
CYTK
ERNA
OUTLOOK RATING
1..100
6218
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
54
Fair valued
PROFIT vs RISK RATING
1..100
45100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5764
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
5065

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ERNA's Valuation (54) in the Medical Specialties industry is somewhat better than the same rating for CYTK (100) in the Biotechnology industry. This means that ERNA’s stock grew somewhat faster than CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (45) in the Biotechnology industry is somewhat better than the same rating for ERNA (100) in the Medical Specialties industry. This means that CYTK’s stock grew somewhat faster than ERNA’s over the last 12 months.

CYTK's SMR Rating (100) in the Biotechnology industry is in the same range as ERNA (100) in the Medical Specialties industry. This means that CYTK’s stock grew similarly to ERNA’s over the last 12 months.

CYTK's Price Growth Rating (57) in the Biotechnology industry is in the same range as ERNA (64) in the Medical Specialties industry. This means that CYTK’s stock grew similarly to ERNA’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for ERNA (100) in the Medical Specialties industry. This means that CYTK’s stock grew significantly faster than ERNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKERNA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
87%
MACD
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
76%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
74%
Bullish Trend 1 day ago
87%
Advances
ODDS (%)
N/A
Bullish Trend 8 days ago
84%
Declines
ODDS (%)
Bearish Trend 6 days ago
75%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
89%
Aroon
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ERNA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FLCH19.720.23
+1.18%
Franklin FTSE China ETF
SLYG90.770.47
+0.52%
SPDR® S&P 600 Small Cap Growth ETF
AVES50.130.17
+0.34%
Avantis Emerging Markets Value ETF
HISF44.290.11
+0.25%
First Trust High Income Strat Foc ETF
SBB15.04-0.06
-0.40%
ProShares Short SmallCap600

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with KRON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then KRON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
-0.66%
KRON - CYTK
43%
Loosely correlated
-4.04%
IOVA - CYTK
42%
Loosely correlated
+2.41%
DARE - CYTK
42%
Loosely correlated
-5.53%
CKPT - CYTK
41%
Loosely correlated
-0.71%
DSGN - CYTK
40%
Loosely correlated
+2.31%
More

ERNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERNA has been loosely correlated with CGEN. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ERNA jumps, then CGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERNA
1D Price
Change %
ERNA100%
+2.88%
CGEN - ERNA
39%
Loosely correlated
-4.09%
MDGL - ERNA
36%
Loosely correlated
+3.67%
IBIO - ERNA
32%
Poorly correlated
N/A
SMMT - ERNA
31%
Poorly correlated
+5.11%
CYTK - ERNA
29%
Poorly correlated
-0.66%
More